About The Cover

COVER An analysis of pharmaceutical payments to physicians after they voted on drug approval recommendations suggests that the Food and Drug Administration (FDA) needs to consider whether prospects of future rewards could influence its advisory panels. The investigation also indicates that the FDA may have missed more traditional conflicts of interest for those advisers. Another story looks at revolving-door concerns for FDA staff. See p. 16.
ILLUSTRATION: STEPHAN SCHMITZ